6 medicines that moved to the next trial phase this week
6 medicines from company sponsors entered a higher trial phase in trials registered on ClinicalTrials.gov from 10 November 2026 to 16 November 2026; the 6 below lead by phase and trial size.
As of . Research from public records, not investment advice.
- QLS4131 (Qilu Pharmaceutical Co., Ltd.): First Phase 3 trial, after Phase 2 trials. Relapsed or Refractory Multiple Myeloma, 300 participants planned.
- S-Ibuprofen Gel 5% (Aponia Laboratories, Inc.): First Phase 3 trial, after Phase 2 trials. Acute Pain Due to Trauma, 240 participants planned.
- Sutacimig (Hemab ApS): First Phase 3 trial, after Phase 2 trials. Thrombasthenia, 76 participants planned.
- ABBV-722 (AbbVie): First Phase 2/3 trial, after Phase 2 trials. Systemic Sclerosis, 580 participants planned.
- NP-101 (Novatek Pharmaceuticals): First Phase 2/3 trial, after Phase 2 trials. Gastroenteropancreatic Neuroendocrine Tumors, 381 participants planned.
- GR2301 injection (Genrix (Shanghai) Biopharmaceutical Co., Ltd.): First Phase 2 trial, after Phase 1/2 trials. Vitiligo, 120 participants planned.
How this list is made
A medicine counts when a company sponsor registers a trial of it on ClinicalTrials.gov at a higher phase (Phase 2, 2/3 or 3) than any of its earlier trials of the same drug, on ClinicalTrials.gov or the EU trials register (CTIS). The lead drug of each trial is used; placebo and standard-of-care arms are left out, and drug names are compared without doses or forms. A line says first when no earlier trial of the drug at that phase exists on either register, from any sponsor, and new otherwise. A new trial is a registration, not a result.
Sources: ClinicalTrials.gov, EU Clinical Trials Information System (CTIS).